Merck & Co. Inc. (NYSE:MRK) on Thursday released results from the Phase 3 STRIDE-13 trial evaluating Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) at the European Society of Clinical ...
October 12, 2012 — An advisory committee to the Centers for Disease Control and Prevention has released recommendations on the use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE ® (Pneumococcal ...
HONG KONG, Jun 20, 2025 - (JCN Newswire) - - Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to life-threatening illness. It is also the single ...
A new vaccine for pneumococcal disease will be tested under an international trial aiming to provide greater protection to babies against the common infection that causes pneumonia, sinusitis and ...
Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...
Questions are answered by experts at the Oregon Health Authority, other state agencies or community partners. Questions and answers are republished by permission. Q: I am in my 70s and have previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results